CAJ | 학술논문

目的分析转移性三阴乳腺癌(MTNBC)患者临床病理学特征及生存状态,探讨其复发转移部位尤其脑转移特点.方法收集了 2002年1月至2004年12月天津医科大学肿瘤医院收治的120例MTNBC患者的临床资料,回顾性分析其临床病理学特征及生存情况.采用SPSS 13.0统计软件进行分析,取P＜0.05差异有统计学意义.结果至随访截止期,120例MTNBC患者转移后中位生存时间为22个月,死亡79例(65.8%).肺、肝、脑是常见的转移部位,分别为70例(58.3%)、50例(41.7%)和49例(40.8%).其中22例(18.3%)首发转移部位为脑转移,其生存期较非脑转移患者明显缩短,转移后中位生存时间为8个月和31个月(P=0.000).结论 MTNBC患者预后差,其中脑转移较非脑转移明显影响本组患者的预后,探索新的更有效的治疗手段将成为今后的研究热点.
목적 분석전이성삼음유선암(MTNBC)환자림상병이학특정급생존상태,탐토기복발전이부위우기뇌전이특점.방법 수집료 2002년1월지2004년12월천진의과대학종류의원수치적120례MTNBC환자적림상자료,회고성분석기림상병이학특정급생존정황.채용SPSS 13.0통계연건진행분석,취P＜0.05차이유통계학의의.결과 지수방절지기,120례MTNBC환자전이후중위생존시간위22개월,사망79례(65.8%).폐、간、뇌시상견적전이부위,분별위70례(58.3%)、50례(41.7%)화49례(40.8%).기중22례(18.3%)수발전이부위위뇌전이,기생존기교비뇌전이환자명현축단,전이후중위생존시간위8개월화31개월(P=0.000).결론 MTNBC환자예후차,기중뇌전이교비뇌전이명현영향본조환자적예후,탐색신적경유효적치료수단장성위금후적연구열점.
Objective To analyze the clinical features and survival for patients with metastatic triple negative breast cancer ( MTNBC), especially such a metastatic site as brain. Methods The clinical data and survival status of 120 cases of operable MTNBC treated at our hospital from January 2002 to December 2004 were collected. SPSS 13.0 software was used for statistic treatment. Statistical significance was considered at P < 0. 05. Results At the time of last follow-up, the median time after metastasis was 22 months. Nine deaths(65.8% )were recorded. In terms of all metastatic sites (initial + subsequent), lung (58. 3% ), liver(41.7% )and brain (40. 8% ) were most common sites. The patients with brain metastasis had a worse survival than those with non-brain metastases. Twenty-two ( 18. 33% ) patients were found to have brain metastasis at the time of first metastatic presentation. The initial metastatic site in patients with brain metastasis had a worse survival than those with non-brain metastases. The median survival time after metastasis was 8 and 31 months respectively ( P = 0. 000). Conclusion Triple-negative breast cancer is associated with a poor survival after metastases. The patients with brain metastases have a worse survival than those with non-brain metastases. New treatment strategies are needed.